Syndax Pharmaceuticals (SNDX) Cash & Equivalents (2015 - 2026)

Syndax Pharmaceuticals' Cash & Equivalents history runs 12 years deep, the most recent figure standing at $130.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 15.0% year-over-year to $130.9 million; the TTM figure through Mar 2026 stood at $130.9 million (down 15.0% YoY), while the FY2025 annual figure was $134.9 million, down 12.43% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $130.9 million, down from $134.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $295.4 million in Q4 2023, with the low at $57.5 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $116.8 million (2025), against an average of $126.6 million.
• Peak annual rise in Cash & Equivalents reached 297.27% in 2023, while the deepest fall reached 69.53% in 2023.
• Syndax Pharmaceuticals' Cash & Equivalents stood at $74.4 million in 2022, then soared by 297.27% to $295.4 million in 2023, then sank by 47.84% to $154.1 million in 2024, then retreated by 12.43% to $134.9 million in 2025, then retreated by 2.99% to $130.9 million in 2026.
• Business Quant data shows SNDX's Cash & Equivalents at $130.9 million in Q1 2026, $134.9 million in Q4 2025, and $116.8 million in Q3 2025.